Update - Consideration of Xtandi on the PBS pre chemo

[Paul Edwards 32]

At its November meeting the Pharmaceutical Benefits Advisory Committee was considering whether Enzalutamide ( Brand name Xtandi) should be made available on the Pharmaceutical Benefits Scheme (refer to this previous post on the subject)

 

One of the members in last week's teleconference asked when would we know the outcome of that meeting?

 

Today the Pharmaceutical Benefits Advisory Committee published the outcomes from its July meeting.

 

At this rate we won't know the outcomes of their November meeting until April next year.

 

[Edit 18 December 2015 PBAC published its recommendation. Click on this link to find out more.]